Thrombolytic therapy for pulmonary embolism: reversal of shock in the early postoperative period. 1994

S A Nasraway, and N Kabani, and K R Lawrence
Department of Anesthesia, New England Medical Center, Boston, Massachusetts 02111.

Life-threatening acute pulmonary embolism (PE) associated with circulatory shock requires effective therapy directed at removing the obstruction to flow in the pulmonary vasculature and improving hemodynamics. Options for treatment are pulmonary embolectomy and thrombolytic therapy. Although safe and effective, thrombolytic therapy is relatively contraindicated within 10 days of major surgery due to the risk of bleeding. Intravenous streptokinase was administered to a man on the third postoperative day for treatment of a massive PE associated with circulatory shock. Within 2 hours of initiating therapy, the patient experienced marked improvement in hemodynamics and tissue perfusion. No bleeding complications were noted. This case demonstrates that intravenous thrombolytics may be administered safely to patients who have recently undergone surgery. It also underscores that the decision to apply the therapy when relatively contraindicated must be made on an individual patient basis and thus ensure that potentially life-saving therapy is not withheld from those who require it most.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008297 Male Males
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012769 Shock A pathological condition manifested by failure to perfuse or oxygenate vital organs. Circulatory Collapse,Circulatory Failure,Hypovolemic Shock,Collapse, Circulatory,Failure, Circulatory,Shock, Hypovolemic
D013300 Streptokinase Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-. Avelizin,Awelysin,Celiase,Distreptase,Kabikinase,Kabivitrum,Streptase,Streptodecase

Related Publications

S A Nasraway, and N Kabani, and K R Lawrence
April 1992, American journal of surgery,
S A Nasraway, and N Kabani, and K R Lawrence
February 1986, Critical care medicine,
S A Nasraway, and N Kabani, and K R Lawrence
December 1996, Journal of clinical anesthesia,
S A Nasraway, and N Kabani, and K R Lawrence
April 2021, The Cochrane database of systematic reviews,
S A Nasraway, and N Kabani, and K R Lawrence
June 2014, JAMA,
S A Nasraway, and N Kabani, and K R Lawrence
September 2015, The Cochrane database of systematic reviews,
S A Nasraway, and N Kabani, and K R Lawrence
January 1998, Archives of internal medicine,
S A Nasraway, and N Kabani, and K R Lawrence
May 1993, Chest,
S A Nasraway, and N Kabani, and K R Lawrence
December 2018, The Cochrane database of systematic reviews,
S A Nasraway, and N Kabani, and K R Lawrence
April 2006, The Cochrane database of systematic reviews,
Copied contents to your clipboard!